Dr. Reddy’s Lab’s Q1FY25 Quarter Results
Dr. Reddy’s Lab’s revenue grew 14% YoY
- 31 Jul 2024
Read Full Article >
- Dr. Reddy’s Lab reported an 8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter ended June (Q1FY25). On a year-on-year (YoY) basis, it witnessed a growth of 14%.
- Its expenses for the quarter were up by 5% QoQ and 18% YoY.
- The net profit grew 6% QoQ and reduced 1% YoY.
- The earnings per share (EPS) of Dr. Reddy’s Lab stood at 83.5 during Q1FY25.
Dr. Reddy’s Lab’s Financial Statements for Q1FY25:
| (Rs, crores) | Q1FY24 | Q4FY24 | Q1FY25 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total income | 6,932 | 7,311 | 7,883 | 8% | 14% |
Total expenses | 5,086 | 5,710 | 6,007 | 5% | 18% |
Profit before tax | 1,850 | 1,605 | 1,883 | 17% | 2% |
Tax | 445 | 295 | 490 | 66% | 10% |
Profit after tax | 1,405 | 1,310 | 1,392 | 6% | -1% |
Earnings per share | 84.4 | 78.5 | 83.5 |
Financials:
- Net Profit: Reported a slight decline of 1% to ₹1,392 crores.
- Revenue: Increased by 14% YoY to ₹7,883 crores compared to ₹6,932 crores in the previous year.
- EBITDA: Rose by 1.1% to ₹2,160 crores, up from ₹2,137.2 crores in Q1FY24.
- EBITDA Margin: Dropped by 80 basis points to 28.2% from 29% in the same period last year.
- Earning per share: ₹83.5
- Stock Split: Announced a 1:5 stock split; record date yet to be set.
Management Commentary:
Commenting on the results, Co-Chairman & MD, G V Prasad said,
“We had a good start to the new fiscal year, and our growth and profitability were mainly driven by our generics business. We continue to strengthen our core businesses and have made strategic investments in biologics, consumer healthcare, and innovation to drive patient impact and value creation.”
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Open Demat Account
